Coya Therapeutics, Inc. COYA
5.08
(0.10)
(1.93%)
as of 25 Sep
- Market cap
- $121.5M
- P/E
- 0.0×
Follow COYA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17.11 | 11.24 | 12.21 | 23.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.60) | (14.37) | (96.35) | (84.36) | |
P/B ratio |
3.17 | 1.82 | 2.26 | 3.50 | |
Price to Tangible BV |
3.17 | 1.82 | 2.26 | 3.50 | |
EV/Sales |
13.34 | 6.48 | 7.95 | 20.11 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.81) | (3.64) | (5.88) | (6.61) | |
EV/FCF |
(6.02) | (3.18) | (5.31) | (6.34) | |
Quick Ratio |
12.29 | 14.30 | 7.97 | 7.67 | |
Current Ratio |
13.40 | 15.02 | 8.50 | 8.73 | |
Net Debt/EBITDA |
6.13 | 6.64 | 7.77 | 11.59 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.20 | 0.17 | 0.17 | 0.12 | |
Operating CF/Net income |
1.11 | 0.86 | 0.18 | 0.53 | |
Capex/Depreciation |
(0.61) | (316.07) | (94.00) | (75.88) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,064.30% | 1,631.46% | 124.76% | 81.84% | |
Selling, General and Administrative Expense of Revenue |
925.56% | 1,506.17% | 82.57% | 71.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
387.32% | 874.35% | 27.87% | 30.05% | |
Graham Net Nets |
0.31 | 0.55 | 0.44 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.29%) | (29.19%) | (21.90%) | (19.47%) | |
Free Cash Flow Yield |
(12.95%) | (18.12%) | (12.27%) | (13.27%) | |
Revenue per Share |
0.01 | 0.01 | 0.24 | 0.21 | |
Operating CF per Share |
(0.31) | (0.27) | (0.06) | (0.07) | |
Capex per Share |
0.00 | (0.04) | (0.04) | (0.03) | |
Free Cash Flow per Share |
(0.31) | (0.31) | (0.10) | (0.10) | |
Cash per Share |
1.84 | 2.24 | 2.80 | 1.68 | |
Shareholders Equity per Share |
1.84 | 2.16 | 2.57 | 1.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.84 | 2.16 | 2.57 | 1.63 | |
Free Cash Flow |
(7.38) | (7.09) | (1.66) | (1.65) | |
Working Capital |
43.55 | 49.72 | 44.07 | 28.36 | |
Capital Expenditures |
0.00 | (0.88) | (0.65) | (0.52) | |
Net Current Asset Value |
43.03 | 48.96 | 43.02 | 27.27 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 3.52 | 0.16 | 0.14 | |
Net Profit Margin |
(2,723.96%) | (2,870.17%) | (144.15%) | (59.36%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.01 | 1.32 | 1.32 | 0.72 | |
Average Assets |
40.38 | 45.84 | 47.15 | 33.80 | |
Average Common Equity |
35.79 | 41.17 | 41.30 | 29.65 |
Columns are period end dates